TABLE 1.
Results for the Base-Case for Resmetirom Compared With Standard Care, Health Care Sector Perspective
| Treatment | Drugcost a | Totalcost | QALYs | evLYs | Incremental cost-effectiveness ratio | |
|---|---|---|---|---|---|---|
| Cost per QALY gained | Cost per evLY gained | |||||
| Resmetirom | $76,000 | $416,000 | 10.66 | 10.74 | Less costlyMore effective | Less costlyMore effective |
| Standard care | $0 | $439,000 | 10.05 | 10.05 | Comparator | Comparator |
a Placeholder price based on Javanbakht et al 2022. 8
evLY = equal value of life-year; LY = life-year; QALY = quality-adjusted life-year.